PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Versartis Initiates First Clinical Trial for New Diabetes Drug VRS-859 (exenatide-XTEN)
– Phase I Study for Monthly Dosing of Type 2 Diabetes Mellitus Drug –
View HTML
Toggle Summary Versartis Presents Results of Three Studies at ENDO 2010
– Growth Deficiency Advisory Board Greatly Expanded –
View HTML
Toggle Summary Versartis CEO Jeffrey Cleland Featured at Advancing Protein Therapeutics Conference
– Monthly Dosing of Drugs for Metabolic and Endocrine Diseases is Company’s Focus –
View HTML
Toggle Summary Paul Westberg Joins Versartis as Senior Vice President, Business Development
- Focus on Transactions for Novel Therapeutics –
View HTML
Toggle Summary Versartis to Present New Data at International Congress on Endocrinology
- Posters will Illustrate Progress of Company’s Drugs for Metabolic and Endocrine Diseases -
View HTML
Toggle Summary Versartis to Present at Biotech Showcase in San Francisco
– Company Focused on Extending the Half-Life of Drugs for Metabolic and Endocrine Diseases –
View HTML
Toggle Summary XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics
XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics Redwood City and Mountain View, CA  – November 15, 2009 – Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology
View HTML
Toggle Summary Versartis Presents Preclinical Data for Novel Type 2 Diabetes Drug
New Compounds Extend Half-Life for Monthly Dosing
View HTML
Toggle Summary Versartis to Provide Update on Product Pipeline at Two Technology Conferences
New Technology Being Used to Extend Half-Life of Drugs for Metabolic and Endocrine Diseases
View HTML
Toggle Summary SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes AMSTERDAM, August 17 - SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel
View HTML